Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fractyl HealthGUTS -2.91%10 6-1 Month Momentum % is 34.05% as of Sep. 04, 2026. GuruFocus rates GUTS with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,379 Biotechnology companies, Fractyl Health ranks better than 89.2% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-09-04), Fractyl Health's 6-1 Month Momentum % is 34.05%.
The industry rank for Fractyl Health's 6-1 Month Momentum % or its related term are showing as below:
GUTS's 6-1 Month Momentum % is ranked better than 89.2% of 1379
companies
in the Biotechnology industry
Industry Median: -16.72
vs GUTS: 34.05
Fractyl Health (NAS:GUTS) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Fractyl Health 6-1 Month Momentum % Related Terms
GUTS vs PYPD, PLYX, COYA: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, Fractyl Health's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fractyl Health 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fractyl Health's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Fractyl Health's 6-1 Month Momentum % falls into.
Fractyl Health (NAS:GUTS) 6-1 Month Momentum % Calculation
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum %
=
( Price 1-month ago
/
Price 6-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fractyl Health (GUTS) has a 6-1 Month Momentum % of 34.05% as of Sep. 04, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Fractyl Health and its competitors. According to the industry distribution chart, Fractyl Health ranks #149 out of 1379 companies in the Biotechnology industry, placing it in the top 10.8%.
Is Fractyl Health's 6-1 Month Momentum % too high?
Fractyl Health's current 6-1 Month Momentum % is 34.05%. Based on the distribution chart, Fractyl Health ranks #149 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fractyl Health has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Fractyl Health's 6-1 Month Momentum % compare to PYPD and PLYX?
According to the Biotechnology industry distribution chart, Fractyl Health ranks #149 out of 1379 companies for 6-1 Month Momentum %. This places Fractyl Health in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Fractyl Health and its competitors. Fractyl Health's current 6-1 Month Momentum % is 34.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fractyl Health stock overvalued right now?
Fractyl Health (GUTS) has a current 6-1 Month Momentum % of 34.05%. The current 6-1 Month Momentum % is 34.05%. Fractyl Health's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Fractyl Health (GUTS), the current 6-1 Month Momentum % is 34.05% as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
10GF Score
Get the complete analysis for GUTS
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GUTS has been successfully added to your 
